Merck & Company Inc. (NYSE:MRK)

Chart of the Day July 16th, 2022

View Entire Video (49:01)
Chart of the Day
July 16th, 2022
  00:01
Chart of the Day
July 15th, 2022
  00:00
Chart of the Day
July 14th, 2022
  00:15
Chart of the Day
July 14th, 2022
  01:24
Chart of the Day
July 12th, 2022
  00:20
Chart of the Day
May 20th, 2022
  00:06
Chart of the Day
May 5th, 2022
  01:47
Chart of the Day
May 2nd, 2022
  00:31
Chart of the Day
January 7th, 2022
  00:08
Chart of the Day
December 17th, 2021
  00:19
Chart of the Day
October 7th, 2021
  01:22
Chart of the Day
October 7th, 2021
  01:22
Chart of the Day
January 25th, 2021
  00:52
Strategy Session
May 26th, 2020
  01:31
Strategy Session
April 8th, 2020
  00:01
Strategy Session
September 19th, 2019
  00:01
Strategy Session
April 1st, 2019
  00:06
Strategy Session
February 12th, 2019
Price Alert 00:21
Strategy Session
February 11th, 2019
  00:27
Strategy Session
January 22nd, 2019
  01:51
Sector Spotlight
November 30th, 2018
  06:00
Strategy Session
November 19th, 2018
  00:12
Stock Watch
November 16th, 2018
  00:02
Strategy Session
November 5th, 2018
  00:17
Market Overview
September 21st, 2018
  00:01
Strategy Session
August 6th, 2018
  00:28
Strategy Session
June 14th, 2017
  00:50
Strategy Session
January 31st, 2017
  00:29
Strategy Session
June 14th, 2016
  01:20
Strategy Session
June 1st, 2016
Price Alert 00:05
Market Overview
April 29th, 2016
  01:17
Chart of the Day
April 6th, 2016
  00:54
Strategy Session
November 9th, 2015
  01:49
Strategy Session
November 11th, 2014
  00:08
Strategy Session
May 6th, 2014
  00:14
Stock Watch
February 16th, 2014
  00:10
Strategy Session
July 22nd, 2013
  00:06
Sector Spotlight
June 14th, 2013
  00:23
Strategy Session
May 16th, 2013
  00:30
Stock Watch
April 12th, 2013
  00:20
Strategy Session
April 12th, 2013
  00:15
Strategy Session
April 11th, 2013
  00:15
Strategy Session
April 10th, 2013
  01:52
Strategy Session
April 4th, 2013
  00:39
Strategy Session
April 3rd, 2013
  01:26
Strategy Session
April 2nd, 2013
  00:04
Strategy Session
April 1st, 2013
  01:12
Strategy Session
March 26th, 2013
  00:01
Strategy Session
March 26th, 2013
  00:23
Chart of the Day
December 13th, 2012
  02:27
Bands Volume 200 SMA 50 SMA 20 SMA Videos Alerts Articles Events
MRK Weekly Chart

Old Forum Content for MRK

Make a Forum Post
Become a member to view recent forum posts. Already a member? Sign in here.
Loading...
  • woodman: $PDSB - I'm rebuilding a position in this one. Lots of important catalysts coming in October. Deep pipeline. It has some collaborations with $MRK (combo with Merck's Keytruda which is the SOC in those areas currently, but Merck needs to extend its patent so is in a lot of trials with other companies' cancer drug candidates). It's also working with with Mayo Clinic, MD Anderson and NIH/NCI. See pipeline here: https://www.pdsbiotech.com/index.php/pipeline/pipeline-oncology Currently trading at $6.32 (up from $4.62 Friday last week). Price targets: Cantor $25; HCW $21; Oppy $24; CG Capital $18. For some good info, see if you can get CG Capital's latest report from August. Google "CGCapital PDSB" then hit the images tab at top of your browser (if using Chrome, this works). Not sure if it will bring up this most recent report (August); it may only give you an earlier one.
  • sierramp: @woodman $PDSB $MRK Thank you for sharing your research. Impressive collaborations, partner funded trials and PTs. The number of funds with ownership has been climbing, now at 82. I took a starter.
  • woodman: @sierramp $PDSB $MRK - You're welcome, and good luck!
  • jwstich: @woodman $PDSB $MRK. I took a very small pilot position. Thanks for your hard work and generosity.
  • bud_ozborn: I am seeing movement out of tech names and into pharma and banks RED $DDOG $SPLK $ARKK $CRWD green $ABT $LLY $BMY $MRK $PFE $KEY $PACW $SCHW $GS $STNE $NU
  • woodman: $PDSB - I'm still in this and have been adding (both before and after the 5/25 pre-ASCO data announcement for one of its many cancer trials). It will be presenting a fuller picture of the recent data at ASCO in the afternoon on Mon. 6/5 followed by a ...
  • gtr89: @woodman $PDSB $MRK thanks for the $PDSB update. Nice move on volume today. I still have my full position and intend to keep holding, but it is tempting to take some off
  • woodman: @gtr89 $PDSB $MRK - I'm sticking with mine through ASCO and following presentation/conference call. Then I'll decide what to do in terms of taking some off to use the $$ elsewhere. There are a number of biotechs I'd like to add to, but I have to sell things to do that. It's a lot of whack-a-mole and threading needles to try to rotate money around these without missing a catalyst run in one while taking advantage of dips in others. And PDSB has so much going on, it may be hard to sell without missing the next catalyst run.
  • wpsimril: $MRK Nice BO; will volume hold it up?
  • woodman: $TERN $VKTX $MDGL $ETNB - $MRK just bought Prometheus (immunology) before Phase 3 has started. I think there was another recent acquisition of a company with a Phase 2 drug.
  • woodman: Big announcement that $MRK is acquiring $RXDX (immunology space). RXDX (up almost 80% today on this news) has no Phase 3 drug, which is kind of amazing. Shows that Big Pharma is really on the hunt for new therapies in big markets. I think it makes $VKTX even more attractive and it's coming 2Q Phase 2B data for its NASH drug (another big market) will be very important. If successful, one can reasonably believe it to be an acquisition target even though not at the Phase 3 finish line. It also has early good Phase 1 data for its obesity drug. Granted, that's far from the finish line, but it's an added something for Big Pharma if already interested in the NASH drug. It has other stuff in the pipeline as well to add spice to any thoughts by Big Pharma of scooping up VKTX for NASH. Just some food for thought.
  • joelsg1: @woodman $MRK $RXDX $VKTX Nice call, and for awhile!
  • woodman: @woodman $MRK $RXDX $VKTX - Thank you, and also for ignoring my stinkers. :-) Speaking of my stinkers, $XFOR rose from the dead last week. It had a nice pop on late breaking data and news that it will be presenting at the Clinical Immunology Society on 5/16 to provide an update on US regulatory activities in support of potential NDA submission for its Mavorixafor for WHIM (warts, hypagammaglobulinemia, infections, and mylokathexis). It's now flagging just under the 200d barrier.
  • debeers: $MRK-morning news: Merck announces the FDA accepted application for KEYTRUDA plus chemotherapy as first-line treatment for locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma 6:46 AM ET, 04/13/2023 - Briefing.com The sBLA is based on data from the KEYNOTE-859 trial, in which KEYTRUDA plus chemotherapy demonstrated a statistically significant improvement in overall survival (OS) versus chemotherapy alone, regardless of PD-L1 expression, in patients who were human epidermal growth factor receptor 2 (HER2) negative. The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action, date of December 16, 2023.
  • debeers: $MRK-seems like once a month or so there is a new indication for Keytruda and it is my choice for the cancer space where other less extreme drugs have failed,
    Also, IMO no matter what, even if a recession comes and you are forced to delay your cruis ...
  • debeers: $MRK-B of A raises from neutral to buy. Recent on head and neck cancer impressive. Under a half an hour away from the Goldman Sachs conference.
  • debeers: Scrapped $PYPL and $AEM Added $BKE &$SLB ( or if you are in for a day GUSH) i'm not so $SLB as oil going back up $ACHR/$ARDX/$BA/$BKE/$MRK/$SLB/$WYNN LONGS ALL
  • debeers: $MRK- LONG FORM--from the conference Keytruda and Guardacil expand their uses and ease of administering. There is no other cancer vaccine at the current time. They are also involved in animal health and immunology. Acceleron acquisition endpoints keep being moved out and he paticept.Acceleron phase 3 team fully supported and Merck has made these acquisitions before and are recruiting faster than before. LVL biomarker research is something that they believe can be delivered in an oral drug. Considering that an elevated LVL has a direct relationship to cardio disease and death- this critical research and development. They are continuing to monitor antivirals as relatrd to Covid and other viruses. SHORT FORM: Expectation that phase 3 trials will succeed with FDA high. Merck has very few misses.LONG
  • debeers: $MRK- So here's what the IBD had to say: much more eloquently than i did while listening to the healthcare conference call:
    LONG FORM;In the span of a month in late 2022, Merck (MRK) gained a new chief executive, announced a $1.35 billion takeover a ...
  • debeers: $BA-how many airlines are there.2. $CF-just a bit $MRK-makes its numbers and does its own due dil so i don't have to police it $SCHW-early because it won't go up really until the 2nd half. i have to go to the analyst meeting and then i wll hear what the brokers are asking $SLB & $VLO are we replacing reserves? NO. Are we recognizing that energy is, along with food, a necessary commodity and a refiner and a servicer is where i want to be $TMUS-Delta gave TMUS a present today. It announced free wi-fi for its customers in flight and its the only carrier AND they didn't even put it to bid! Yowza! Instant revenue increase for $TMUS
  • scottrades: My notes: $SPY Awaiting more Data $QQQ Awaiting Apple’s Breakdown $DIA Tap Dancing on the trendline $XLE Back in the range $GDX Holding up $KWEB Holding the gap $XHB Dan added some stocks to the ATL $XBI Tight $AAPL Not a good look. $MSFT The future? $BABA Strength in some China Stocks. $PDD Breaking out $KRYS Dan mentioned this one $CPRX I own this $ACLX Trying to move out of a base $LABU For those who like to live dangerously $MRK Breaking out $FCX Copper trying to move $WPM Still own this. $NEM Holding up. $GOLD 200 Day Support $XOM Sling Shot? Watch 110 $CROX Mentioned in the forum $CELH at the 50 Day $PLNT It is January $SBUX Clear resistance $BOX Nope.
  • debeers: LONGS ALL- $BA- since 140, $NEM will do way better than GDXJ imo, $NKE, sneaking upward, $PYPL, $WYNN er winner chicken dinner. Will add $MRK back--big mistake to have removed it. I gave the reason yesterday why i prefer picking a stock to an etf.
  • debeers: $MRK -back in 111.56. Why? 3 upgrades BEFORE THE GOLDMAN SACHS CONFERENCE TOMORROW. you might get it for a few pennies less but here's the why of the buy: 1. Baird upgrade 2.$MRK-Immutep achieves 50% enrollment milestone in randomised phase IIb TACTI-003 trial for first line head & neck cancer 6:24 AM ET, 01/04/2023 - Briefing.com Co announces that it has enrolled and randomised over 50% of the planned 154 patients in the TACTI-003 Phase IIb trial. TACTI-003 is evaluating Immutep's first-in-class soluble LAG-3 protein eftilagimod alpha ("efti"), in combination with MSD's (MRK) anti-PD-1 therapy KEYTRUDA (pembrolizumab) as 1st line treatment of recurrent or metastatic head and neck squamous cell carcinoma (1L HNSCC). 3. GS has always had $MRK as a top pick
  • jpoko13: @debeers $MRK bought a starter...I like your synopsis
  • woodman: $LVS breakout - Besides LVS, I'm in very little other than a number of select biotech stocks. My non-biotech is LVS $NFLX (bought this morning) $ELF $GDXJ, and big pharma $MRK and $LLY
  • jonwest88: @woodman @champ $LVS $NFLX $ELF $GDXJ $MRK $LLY Ulta Beauty $ULTA since 11/15 approx., this one has returned about the same as $ELF.
  • woodman: @jonwest88 $LVS $NFLX $ELF $GDXJ $MRK $LLY $ULTA - I love the consolidation in $ELF after a monster 170+ % run from May 2022 (vs Ulta 45%). ELF is taking a well deserved and encouraging rest as it consolidates into the rising 50d which has almost caught up. I think ELF is preparing for another move higher soon. Maybe not this week, but soon. I continue to hold it. I have to check my notes but I think I bought it back in August. (Maybe earlier, I can't recall.)
  • jonwest88: @woodman $LVS $NFLX $ELF $GDXJ $MRK $LLY $ULTA HAVE put $ELF on the watch, as I have had a small bit of $ULTA since 9/1 and mid Oct. Lucked out with Cramer rave fave $EL. Nice run on that one from below $200 a few months ago
  • woodman: @jonwest88 $LVS $NFLX $ELF $GDXJ $MRK $LLY $ULTA $EL - Excellent work with $EL! Congrats.
  • debeers: $MRK-2 pieces of good news: 1. china grants conditional emergency approval for Merck's Covid treatment- . china grants emergency approval for Molnupiravir This is for use in adults with risk of Covid progressing to severe from moderate. The bodies piling up outside the crematories is not a good look. In my view, there should be 3 waves of the disease: Coastal which should recover first as that is where Covid struck first, 2nd the high population cities and 3rd inland country. In the meantime of course, the Chinese are anxious to travel and spread what they refused for so long to control to everyone else.
  • steve71: @debeers $MRK Good info, thanks.
  • woodman: @debeers $MRK - MRK has a patent cliff in 2028 for its all-star cancer med Keytruda. So, it's machine gun firing around the cancer sphere to find combinations with small biotech drugs/therapies to "extend" the patent. I see so many of these smaller biotechs with their therapies in combo trials with Keytruda. I think there will be gold in some of these combinations.
  • debeers: $MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Robert M. Davis, chairman and chief executive officer, is scheduled to participate in a fireside chat at the Goldman Sachs Healthcare CEOs Unscripted Conference on Thursday, Jan. 5, 2023, at 8:55 a.m. ET. IMO you might want to listen to this one. More for the Questions and comments from Goldman than even what Merck says. Pulled back a few cents because it has run so much. IMO the best is yet to be.
  • Rockstar: ...
    The market had the $IWM, and the $DIA, but those indices have been struggling over the last three weeks. This last week is a week to be careful. Still no oversize positions and this is still a traders market, not a swing market. I am still looking a ...
  • debeers: From the WSJ- In deciding today between choosing a healthcare provider or pharmas, i decided on the pharmas after a really long article in the journal about how healthcare companies are findiong that fewer hospitals are locating in the poorer areas. Drug companies are in the driver seat, therefore, in my opinion. LONG THE MERKSTER$MRK who has lotsa fingers in lotsa cancer pies pies and my spec $ARDX/
  • debeers: $COP/$MRK/$SCHW/$TS-relative strength so far above the others compelled to buy $ARDX-down due to index, not research. Still way above the 20 day but had to sell it. Fell below VWAP.
  • Justhanging48: @debeers $COP $MRK $SCHW $TS $ARDX Taking a starter on $TS. Thank you for posting your actions.
  • Rockstar: ...
    The $XLV bounced off the 50 day EMA yesterday and while it is pushing against the 21 EMA today this is another sector that could be bullish going into the end of the year. $LLY,$MRK, $CI, and $UNH are stocks to review for opportunities in the $XLV ...
  • debeers: AND THEN THERE WERE 5 $ARDX (prem amt same as $BA/$MRK/$NKE/$SCHW)-all premium amounts the same
  • debeers: @SCOTTRADES-why is $NKE showing down here? the stock is UP as is $ARDX/$MRK/
  • woodman: @debeers $ARDX $BA $MRK $NKE $SCHW - Though I'm thinking that $ARDX gets back to about $4-$5 on a favorable FDA decision in a few weeks, note that the gap from CRL back in July 2001 goes to $7.35. So, some good/great potential here.
  • debeers: @woodman $ARDX $BA $MRK $NKE $SCHW -no value judgment just reporting. Likei said, if it gets to 5.25 and wants to go higher---who am i to stop it?
  • debeers: $ARDX/$LEN/$MRK/$NKE-i'll buy back $TECK if it can climb a bit first. i figure maybe a buck or so. Altogether, considering the $BA squish, not a bad day. Now no more $BA and no more $TECK until they fly right and harden up. others Long
  • Mounty: @debeers $ARDX $LEN $MRK $NKE $TECK $BA What do you see as the $LEN driver with increasing interest rates?
  • debeers: @DAN- i know this is selfish of me but it will be my birthday soon and what i would like is for you to do is go on vacay for another week . i have absolutely no idea why this is because no matter what the averages show on the screen, i do really well when you are away so all i am asking is, if you are having a good time could you take just a couple of more days off??? Thanks so much. debeers $ARDX/$LEN/$MRK and $TECK if it goes up another buck or so is when i want to buy it back
  • debeers: @Mounty $ARDX $LEN $MRK $NKE $TECK $BA -IMO and its just me, $LEN has a really nice balance sheet.They are tremendous stewards of cash. i also think that a certain person from Omaha has been sniffing around them.just sayin'
  • debeers: $LEN@Mounty-here's what i see.@Mounty $ARDX $LEN $MRK $NKE $TECK -IMO and its just me, $LEN has a really nice balance sheet.They are tremendous stewards of cash. i also think that a certain person from Omaha has been sniffing around them.just sayin'
  • debeers: $MRK-New drug approved for patients with Metastatic Castration resistant prostste cancer.
  • Henry: @debeers $MRK Jeez, this has to be the first post I see. Ouch..😒 Good news for the patients that have condition because there isn't much else for them.
  • debeers: @Henry $MRK -If i made you reach protectively for your nether regions, sorry H! Desperate times, desperate measures.
  • debeers: $ARDX/$BA/$MRK/$NKE/$SCHW-new/$TECK-LONG
  • woodman: Current #biotech and Big #Pharma that I'm in: $ARDX (gift drop 2 days ago; catalyst with news likely in January - see my prior posts) $CPRX (keeps going) $ORMP (strong today; catalyst into January for P3 results for oral insulin; also, CEO just talke ...
  • debeers: ...
    3. $MRK-Gets priority review from FDA for urothelial cancer
    4A&B --T
    $HAL/$SLB there are things i like about $HAL/$SLB-i think both will outperform the others in energy over the next 12 months
    5.. $SMCI-Addded to the S&P midcap index
    6. $ST ...
  • debeers: $AVGO/$BA/$BOX/$HSY/$MRK/$HSY/$LLY/$MRK/$MSFT/$TXRH-LONGS all.
  • woodman: $MRK trying to break-out of a some consolidation. Not sure it's quite ready though. But keep on radar. I do have a position in this already.
  • woodman: @Justhanging48 $MRNA - news on its melanoma combo therapy with $MRK. Very early stage, however. Could speed along quickly, though.
  • Justhanging48: @woodman $MRNA $MRK Wouldn't chase this as I have seen this situation so many times before. Stocks pops on the story, then fades since it is in a very early stage.
  • woodman: @Justhanging48 $MRNA $MRK - no doubt.
  • debeers: The message for all companies on earnings is that the risk cannot simply beat. Must beat and raise. ideally crush and raise. With that in mind: $CELH/$DXCM/$HSY/$MRK/$STLD/$URI- we already discussed that, with money tight and loans for equipment being more expensive :RENT IT-LONGS ALL
  • issues: @debeers $CELH $DXCM $HSY $MRK $STLD $URI We have all those positions except $DXCM. We compared DXCM to $PODD but didn't buy either.
  • debeers: $CPB/$HSY/$ENPH/$LOW/$M/$MRK/$ULTA- long
  • Rockstar: ...
    The $DIA and $IWM continue their strength with some strength in more than a couple ETF's. The ETF's that I am looking at long positions include $TAN, $XLF, $XLE, $XLB, $XLI, $XLP, $XLV, $XME,and $IYT. Of these, I am hesitant on the $XLE with oi ...
  • Rockstar: ...
    Specific stocks I am looking at for longs are in the health care sector with $JNJ,$ABBV,$VRTX,$MRK,$CI and $UNH on that list. I am also looking at $PEP $COST,$WMT, $TMUS (already long), $NUE $GS and $AXP for longs in the $XLV and $XLF sectors. ...
  • Rockstar: ...
    So what do we do now. I was long the semis ($ON and $NVDA) on Monday, as mentioned in my missive on that day, and sold my positions on Tuesday. In hindsight it would have been a nice hold through yesterday's numbers, but I did not want to hold ...
  • jwstich: @Rockstar and @DAN $SPY $DIA $QQQ $IWM $ON $NVDA $SMH $XLV $AMGN $MRK $VRTX $MCK $XLE $CVX $XOM $DVN $OXY $XLF $GS $MET $AFL Do you still plan on combining SMM and OMM in some fashion? If so, when might this happen? I would be very much interested at looking at the combination. BTW, nice note this am Rocky.
  • DAN: @jwstich $SPY $DIA $QQQ $IWM $ON $NVDA $SMH $XLV $AMGN $MRK $VRTX $MCK $XLE $CVX $XOM $DVN $OXY $XLF $GS $MET $AFL We are just working on the pricing now. I'm hoping that we can even get it done in time for Black Friday...and if not, then early December. It's a priority...there are just some complexities that are under the hood. Sorry for the delay.
  • Rockstar: ...
    I am looking at the $DIA and $IWM for longs. The sectors are $XLB,$XLE,$XLF,$XLV and I am eyeing the $SMH as well. I know that has more to do with the $QQQ's but that sector has shown some strength recently. The stocks I am looking at within thes ...
  • debeers: $MRK-Profit up 20% on Keytruda success. No disappointments here. None.
  • debeers: $MTDR- Raymond James just upped their outlook to 78. The only 1 international that i still have that is down--as i had to give up on $TSLA and $LRCX due to China shennanigans is $MAR and staying with that because of superior earnings history and the stronger dollar has been amazing for travelers to Europe. Otherwise: $MOH reporting 10/26 AMC-NO MISSES $MTDR 10/25 AMC $PPG, $SLB already reported fantastic, $STLD beat whereas someone else's $NUE did not--just saying. When there's not a lot to do, i try to do nothing. Staying away from most consumer discretionary for now and its killin' me. But i know very few folks who are making major expenses now. $MRK-breaking out imo.
  • scottrades: Some #Earnings to be aware of this week: $AAPL $AMZN $MSFT $META $GOOGL $UPS $SHOP $GM $KO $BA $CLF $F $PHG $XOM $HAL $INTC $GE $VLO $MMM $ENPH $V $JBLU $CVX $CMG $BOH $RTX $AJG $DORM $MCD $CAT $WM $LUV $MA $SHW $PINS $SCHN $BMY $MRK $BIIB $ADM $X $SPOT $KEX $KHC $DX
  • Justhanging48: $MRK seems to be headed to 100 with the Vol and price move if it can get thru resistance this 3rd time
  • mopick: @Justhanging48 $MRK, sold mine with a small profit. Triple top looming, see how it does tomorrow.
  • issues: IBD not working due to maintenance but here are the IBD 50 for this week: $CCRN $MTDR $VRTX $WWE $PXD $SRPT $CIVI $EOG $COP $TALO $NOG $HRMY $FANG $SM $PERI $CVI $DVN $DECK $AMN $MOH $AHCO $DAR $MRK $HAE $EBC $HUM $MRO $LW $OXY $AMR $TTC $WAFD $NBIX $HES $APA $VNOM $PDCE $ERF $HCC $SLVM $PCAR $ONB $CORT $GMAB $CVBF $TNK $PNFP $CADE $GBCI $UCBI
  • Maxtrade: @dan Is $MRK a break out?
  • champ: $ENPH....@ $253....this turn could continue, Day-Trade......other boring positions that I'm working.....$OC $CMC $LLY $AZO $FREY $XPER $HNST $AXON $PENN.... .......also Watching $PLL $MRK $GUSH $GBTC and #others..... because the guess is....the markets might turn, at some point...... so for Now....the daily zig-zags are on going....however just about everything seems to be spring-loaded, for a bounce...... and if it happens.... I'm Ready and Waiting. $QQQ....if the tech sector turns, stocks in that sector will have the largest bounce.....and I have a Watch Lists. However for now.....everything is all screwed-up.
  • sgiseller: $MRK $LLY $ABBV starting very small positions in all
  • Rockstar: ...
    Tech health care and semis is where I will look to see if taking a few bullish trades are right for me. I will pay particular attention to the FANGS and some health care such as $MRK and $UNH. There are some potential shorts as well such as $CSCO, $ ...
  • bigbartabs: @Rockstar $HYG $VIX $DXY $MRK $UNH $CSCO $DIS $DE $SPY ... what indicator leads you to the $SPX 3840 level (which I agree with). The 6/13 week high? Keep up your morning thoughts Rocky... all the best.
  • scottrades: ...
    I pointed out a few setups that I’m watching last night. Really interested in the Drug Manufacturers right now, like $MRK and $LLY. Also want to see some more strength in the $SMH Stocks like $AMD $ON $NVDA $MU and the like.

    As Rocky and I ...
  • scottrades: Good volume on $MRK
  • issues: @wjj3 $ZTS prefer $MRK and $LLY
  • scottrades: $MRK Holding the 21 EMA.
  • scottrades: @scottrades $MRK I'm watching this but no trade yet. Want to see it hold strong and take out the highs on volume.
  • scottrades: My notes: *Audio problem on my video tonight. Sorry in advance* $SPY Another Bounce Day $QQQ Constructive Action $DIA Lower High $UUP Be careful as long as this is in an uptrend. $TNX Consolidation? $TLT Wedging up. $SMH Want to watch these $XLE under the 200 Day. $XBI inside Day $TAN Bottom of the range $URA Up on news $ARKK Not bad, but know your levels. $GBTC Up day. $AAPL Nice move today $AMZN Holding up ok $TSLA Holding up ok $MSFT Choppy $NVDA Watch $AMD Watch $ON Potential Inverse H&S $DLTR Mentioned in the forum $MRK Short base $MNST Short Base $MCD Just under resistance $ENPH Watch near the MAs
  • scottrades: $MRK Building a nice base.
  • scottrades: My notes: $SPY/$QQQ Eyes on CPI $UUP/$TNX Watch for a CPI Reaction VIX Still in an uptrend. $GLD Lower Low $GDX Needs a base $XBI Green on the day $XLE Holding the 200 Day $USO Not so great $KWEB China Tech holding the 50 Day $ARKK Holding the 50 Day $SDS Working $QID Working $GBTC Not yet. Watching: $AAPL $AMZN $ZM $TSLA $MSFT $RBA Green on the day $MNST Small base $AZN Basing $MRK Basing $PPC Channel $MCD Look for a move to the bottom of the triangle
  • mopick: $SGEN, being aggressivel pursued by $MRK. NP.
  • vcondry: @mopick $SGEN $MRK $190 calls for august currently around $4 decent trade in their somewhere.
  • jpoko13: $MRK Breaking into blue sky
  • Docoof: @Pokersmith $LLY $BMY $MRK $PPH Reviewing some posts and I noticed your post on $PPH. This looks like a pretty safe and promising way to get exposure in this sector if you’re still in “very cautious” mode (which I am) and don’t want to go bottom fishing. It’s above all the SMAs (on the daily & weekly) and the support levels are very clear and not far below. At a minimum it’s worth watching.Thanks for the helpful post. (Don’t hesitate to critique anything in the above.)
  • Pokersmith: @Pokersmith $LLY Several Drug stocks re-entering buy zones, as per IBD Live , see: $BMY , $MRK For a basket of names and industry diversification....see: $PPH
  • Kid2old: @Mikev200 $ABBV Also have a small position in $ABBV. Watching $LLY $JNJ $MRK $PFE.
  • debeers: $MRK-Euro commission comes through with a formal approval for Keytruda for sdvanced breast cancer treatment. Considering the environment today, it seems to me that really good pharmas are a good place to hide out. Deciding that one needs a drug to survive or ameliorate a severe illness is a considerably different decision than the buying of makeup or a new blouse.
  • Pokersmith: @debeers $MRK see also: $PPH ( Pharma basket )
  • debeers: $HSY/$KO/$LLY/$MPC/$MRK/$ZIM-Like the $MPC a lot and think it will have better margins than the integrateds. The rest never gave me a problem today because pharma is not goin g to let anyonme control their pricing power imo.i was going to sell the ZIM but they dont miss. and regardless of the color here--they actuallhy finished a skosh up.
  • debeers: ...
    i think the 2 you have less overall stress from in the medical space are probably the $LLY alopecia drug (you go Jada!). and $MRK for keytruda-its lead cancer drug.
    In the tech space, i don't want to have to worry about chips of any kind and would r ...
  • wanda1616: @debeers $ZIM $EGLE $LLY $MRK $CRM $PANW $BX $XOM its a shocker but $CRM is actually green today
  • debeers: ...
    $MRK-I don't know how the Keytruda news just gets better and better for Cancer but it does and this time for skin cancer. For most of us except for @bRobert and @snowbound, our skin is the biggest organ of our body.
    $PANW-The gold standard in cyber ...
  • bilipi: @debeers $BX $CRM $KO $HSY $LLY $MRK $PANW $FTNT $XOM $ZIM For the record , I actually love bRobert ( in an acceptable adult male to male and he's married and I'm not gay sense ,... ok ? ) Rule #3 however , will always remain ( through absolutely no fault of Dr b's ) .... never trust a doctor . ( and I can't stop laughing because I played organ in church but I wanted a bigger one and they wouldn't give it to me ! )
  • debeers: @bilipi $BX $CRM $KO $HSY $LLY $MRK $PANW $FTNT $XOM $ZIM #5 -A lot of guys probably want a bigger organ at some time in their lives- for the record i don't want to think about you playing on yours. OH A CHURCH ORGAN--well, okay then.
Visit the Trading Forum to join in the discussion.
Stock Price $131.95
Change 0.00%
Volume 10,189,600

Merck & Co Inc is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products.

Request Video of MRK
Already a member? Sign in here.
Past Month

Leading Peers

Past Month

Lagging Peers

Dan Fitzpatrick

Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:

  • Nightly video Strategy Sessions with a game plan for tomorrow
  • Got a stock you want Dan to look at? Just ask.
  • Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
  • Access to over 90,400 stock analysis videos
  • Access an ever expanding library (90,400) of educational videos that will save you time and make you money

Join a team of friends and traders that have one thing in common; a burning desire to succeed.

Become a Member Today!

Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...

Satisfaction Guaranteed!

Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!